Venture-backed Milestone prices Nasdaq IPO to raise $111 mln
Montréal-based cardiovascular drug maker Milestone Pharmaceuticals Inc has priced its Nasdaq Stock Market initial public offering of 5.5 million common shares at US$15 per unit. The company expects to see proceeds of about $111 million (US$82.5 million). Founded in 2005, Milestone is the developer of etripamil, a nasal spray formulation of calcium channel blockers used to terminate episodes of transient cardiovascular conditions. Milestone raised roughly $220 million in financing. This includes $105 million raised last year, led by RTW Investments and joined by BDC Capital, Domain Associates, Fonds de solidarité FTQ, Forbion, GO Capital, Novo Holdings, Pappas Capital, Tavistock Group, Tekla Capital Management and Venrock.
9 May 2019•3 mins read
